Skip to main content
Trillium Therapeutics Inc. logo

Trillium Therapeutics Inc. — Investor Relations & Filings

Ticker · TRIL ISIN · CA89620X5064 TSX Professional, scientific and technical activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2021-04-23 Regulatory Filings
Country CA Canada
Listing TSX TRIL

About Trillium Therapeutics Inc.

http://www.trilliumtherapeutics.com

Trillium Therapeutics Inc. was a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focused on the discovery and development of innovative therapies for the treatment of cancer, particularly those targeting the immune system and its regulation. Trillium maintained preclinical programs and advanced several candidates through clinical trials in the oncology therapy area. In November 2021, Trillium Therapeutics was acquired by Pfizer Inc. and now operates as an integrated entity within Pfizer's global biopharmaceutical research and development structure, continuing its focus on advancing cancer treatments.

Recent filings

Filing Released Lang Actions
52-109F2R - Certification of refiled interim filings - CEO (E).pdf
Regulatory Filings
2021-04-23 English
Interim MD&A (amended) - English.pdf
Regulatory Filings
2021-04-23 English
Interim financial statements/report (amended) - English.pdf
Regulatory Filings
2021-04-23 English
News release - English.pdf
Investor Presentation Classification · 85% confidence The document is a press release announcing a virtual R&D Day event for investors and analysts, scheduled for April 28, 2021. It includes an agenda overview and webcast information but does not contain any financial statements, detailed financial data, or comprehensive report content. The document length is 3969 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a transcript, earnings release, or regulatory filing. The content focuses on investor communication about an upcoming event, which aligns with an Investor Presentation (IP) type document, as it is intended to provide detailed information to investors about the company's research and development strategy and updates. Therefore, the most appropriate classification is Investor Presentation (IP).
2021-04-22 English
Annual report on form 10-K - English.pdf
Regulatory Filings
2021-04-01 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 95% confidence The document is a short notice from Computershare to Canadian Securities Regulatory Authorities regarding the upcoming Annual General Meeting (AGM) of Trillium Therapeutics Inc. It provides details such as meeting type, record dates, meeting date, location, and proxy material delivery information. The document does not contain any financial data, management discussion, voting results, or detailed report content. It is essentially an announcement about the logistics of the AGM, not the AGM materials themselves or any report. Given the short length (1209 characters) and the nature of the content, this fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an AGM Information document or a Report Publication Announcement. Therefore, the best classification is Regulatory Filings (RNS).
2021-03-25 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.